Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.

ABSTRACT:

Introduction

Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson's Disease (PD). Not only are these effects evident in models of PD and other neurodegenerative disorders but recently in a randomized, double-blind, placebo-controlled clinical trial, a GLP-1R agonist has provided improved cognition motor functions in humans with moderate PD.

Areas covered

In this mini-review, we describe the development of GLP-1R agonists and their potential therapeutic value in treating PD. Many GLP-1R agonists are FDA approved for the treatment of metabolic disorders, and hence can be rapidly repositioned for PD. Furthermore, we present preclinical data offering insights into th

SUBMITTER: Glotfelty EJ 

PROVIDER: S-EPMC10477949 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature